AK150 / Akesobio - LARVOL DELTA

Akeso…announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors (PRNewswire) - "AK150 is currently the only ILT2/ILT4/CSF1R trispecific antibody under development globally and is also Akeso's first trispecific molecule to enter the clinical stage."

New trial • Solid Tumor